Alexion Reports First Quarter 2020 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharma (ALXN) Tops Q1 EPS by 51c, Lowers FY20 Guiadnce
May 6, 2020 6:33 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q1 EPS of $3.22, $0.51 better than the analyst estimate of $2.71. Revenue for the quarter came in at $1.44 billion versus the consensus estimate of $1.36 billion.
GUIDANCE:
Alexion Pharma sees 2020 EPS of $10.45-$10.75, versus the consensus of $11.01. Alexion... More
